These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 14610001)

  • 1. Intracoronary administration of abciximab acutely increases flow through culprit vessels of patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Burzotta F; Romagnoli E; Trani C; Crea F
    Circulation; 2003 Nov; 108(19):e138; author reply e138. PubMed ID: 14610001
    [No Abstract]   [Full Text] [Related]  

  • 2. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.
    Gu YL; Kampinga MA; Wieringa WG; Fokkema ML; Nijsten MW; Hillege HL; van den Heuvel AF; Tan ES; Pundziute G; van der Werf R; Hoseyni Guyomi S; van der Horst IC; Zijlstra F; de Smet BJ
    Circulation; 2010 Dec; 122(25):2709-17. PubMed ID: 21098442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Day-case transfer for percutaneous coronary intervention with adjunctive abciximab in acute coronary syndromes.
    Blackman DJ; Clarke NR; Orr WP; Wilkinson E; Beswick A; Coppock D; Sprigings DC; Banning AP
    Heart; 2002 Apr; 87(4):375-6. PubMed ID: 11907016
    [No Abstract]   [Full Text] [Related]  

  • 4. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in patients undergoing percutaneous coronary intervention.
    Kereiakes DJ
    Circulation; 2000 Dec; 102(25):E186. PubMed ID: 11120710
    [No Abstract]   [Full Text] [Related]  

  • 5. Intracoronary administration of abciximab during percutaneous coronary interventions: should this be the routine and preferred approach?
    Sharma S; Makkar R; Lardizabal J
    J Cardiovasc Pharmacol Ther; 2006 Jun; 11(2):136-41. PubMed ID: 16891291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial.
    Thiele H; Wöhrle J; Hambrecht R; Rittger H; Birkemeyer R; Lauer B; Neuhaus P; Brosteanu O; Sick P; Wiemer M; Kerber S; Kleinertz K; Eitel I; Desch S; Schuler G
    Lancet; 2012 Mar; 379(9819):923-931. PubMed ID: 22357109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Administering abciximab. A new drug for preventing coronary restenosis.
    Strimike CL; Wojcik JM
    Nursing; 1997 Mar; 27(3):32aa-32dd, 32ff. PubMed ID: 9171622
    [No Abstract]   [Full Text] [Related]  

  • 8. Double vessel occlusions after balloon angioplasty treated by stenting and subsequently by abciximab infusion.
    Bertrand OF; Meerkin D; de Guise P; Crépeau J; Bourassa MG
    Can J Cardiol; 2000 Jan; 16(1):83-5. PubMed ID: 10653937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials.
    De Luca G; Verdoia M; Suryapranata H
    Atherosclerosis; 2012 Jun; 222(2):426-33. PubMed ID: 22483166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial.
    Mehilli J; Kastrati A; Schulz S; Früngel S; Nekolla SG; Moshage W; Dotzer F; Huber K; Pache J; Dirschinger J; Seyfarth M; Martinoff S; Schwaiger M; Schömig A;
    Circulation; 2009 Apr; 119(14):1933-40. PubMed ID: 19332467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved clinical outcomes with intracoronary compared to intravenous abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Hansen PR; Iversen A; Abdulla J
    J Invasive Cardiol; 2010 Jun; 22(6):278-82. PubMed ID: 20516508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy.
    Sibbing D; Bernlochner I; Schulz S; Massberg S; Schömig A; Mehilli J; Kastrati A
    J Am Coll Cardiol; 2012 Jul; 60(5):369-77. PubMed ID: 22682553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Instant dissolution of intracoronary thrombus by abciximab.
    Lee CH; Ho KT; Tan HC
    Int J Cardiol; 2005 Sep; 104(1):102-3. PubMed ID: 16137518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal treatment of acute coronary syndromes--an evolving strategy.
    Boden WE; McKay RG
    N Engl J Med; 2001 Jun; 344(25):1939-42. PubMed ID: 11419433
    [No Abstract]   [Full Text] [Related]  

  • 15. Abciximab to prevent vessel closure after angioplasty.
    Med Lett Drugs Ther; 1995 Jun; 37(950):52-3. PubMed ID: 7760769
    [No Abstract]   [Full Text] [Related]  

  • 16. [The AIDA STEMI study].
    Prati F; Limbruno U
    G Ital Cardiol (Rome); 2013 Oct; 14(10):631-5. PubMed ID: 24121885
    [No Abstract]   [Full Text] [Related]  

  • 17. Local delivery versus intracoronary infusion of abciximab in patients with acute coronary syndromes.
    Prati F; Capodanno D; Pawlowski T; Ramazzotti V; Albertucci M; La Manna A; Di Salvo M; Gil RJ; Tamburino C
    JACC Cardiovasc Interv; 2010 Sep; 3(9):928-34. PubMed ID: 20850091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty.
    Wöhrle J; Grebe OC; Nusser T; Al-Khayer E; Schaible S; Kochs M; Hombach V; Höher M
    Circulation; 2003 Apr; 107(14):1840-3. PubMed ID: 12682003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Do low risk patients undergoing percutaneous coronary intervention after pretreatment with clopidogrel need abciximab infusion? Results of ISAR-REACT study].
    Gratsianskiĭ NA
    Kardiologiia; 2004; 44(3):80-1. PubMed ID: 15489837
    [No Abstract]   [Full Text] [Related]  

  • 20. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial.
    Bolognese L; Falsini G; Liistro F; Angioli P; Ducci K; Taddei T; Tarducci R; Cosmi F; Baldassarre S; Burali A
    J Am Coll Cardiol; 2006 Feb; 47(3):522-8. PubMed ID: 16458130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.